Article Sidebar

Published: 2022-08-08
Abstract Views: 846
DOI: https://doi.org/10.52163/yhc.v63i4.368
Issue
Vol. 63 No. 4 (2022)
Section
Articles
How to Cite
Sĩ, N. V. ., Trường, T. X. ., Duy, V. T. ., Thuỷ, N. T. T. ., Dung, P. T. M. ., & Thức, Đỗ M. . (2022). LDL CHOLESTEROL ACHIEVEMENT IN HIGH AND VERY HIGH CARDIOVASCULAR RISK PATIENTS ACCORDING TO EUROPEAN SOCIETY OF CARDIOLOGY 2019 GUIDELINE. Vietnam Journal of Community Medicine, 63(4). https://doi.org/10.52163/yhc.v63i4.368

LDL CHOLESTEROL ACHIEVEMENT IN HIGH AND VERY HIGH CARDIOVASCULAR RISK PATIENTS ACCORDING TO EUROPEAN SOCIETY OF CARDIOLOGY 2019 GUIDELINE

Nguyen Van Si1, Tran Xuan Truong2, Vo Thanh Duy1, Nguyen Thi Thu Thuy1, Pham Truong My Dung3, Do Minh Thuc4
1 University of Medicine and Pharmacy at Ho Chi Minh city
2 Pham Ngoc Thach University of Medicine
3 Nhan Dan Gia Dinh Hospital
4 Giong Rieng Hospital

Main Article Content

Abstract

Objective: To evaluate the rate of target achievement of LDL-C in high and very high cardiovascular
risk patients. Methods: A retrospective study of cardiology outpatient database in Nhan dan Gia
Dinh Hospital from 2020 January to 2021 January was conducted. Prescriptions before and after lipid
investigation were collected to consider the statin prescription behavior. Results: LDL-C targets
were achieved in 29.17% and 8.24% of high risk and very high risk patients, respectively. A majority
(83.46%) were on intermediate intensity and 16.54% were on high intensity statin treatment. Statin
dose increment rate was 23.21% in unachieved LDL-C patients. Conclusion: LDL-C achievement
rates were modest in high and very high cardiovascular risk patients while the statin prescription was
not adequate.

Article Details

Keywords

Dyslipidemia, LDL-C, high and very high cardiovascular risk, statin.

References

[1] Mach F, “2019 ESC/EAS Guidelines for
the management of dyslipidaemias: lipid
modification to reduce cardiovascular riskThe
Task Force for the management of dyslipidaemias
of the European Society of Cardiology (ESC) and
European Atherosclerosis Society (EAS),” Eur.
Heart J., vol. 41, no. 1, pp. 111–188, Jan. 2020.
[2] Bruckert E, “Proportion of High-Risk/Very
High-Risk Patients in Europe with LowDensity Lipoprotein Cholesterol at Target
According to European Guidelines: A
Systematic Review,” Adv. Ther., vol. 37, no.
5, pp. 1724–1736, May 2020.
[3] Petrov I, “Clinical Management of High and
Very High Risk Patients with Hyperlipidaemia
in Central and Eastern Europe: An Observational
Study,” Adv. Ther., vol. 36, no. 3, p. 608, Mar.
2019, doi: 10.1007/S12325-019-0879-1.
[4] Krittayaphong R, “The rate of patients at high
risk for cardiovascular disease with an optimal
low-density cholesterol level: a multicenter study
from Thailand,” J. Geriatr. Cardiol., vol. 16, no.
4, p. 344, 2019.
[5] Vrablik M, “Lipid-lowering therapy use in
primary and secondary care in Central and
Eastern Europe: DA VINCI observational study,”
Atherosclerosis, vol. 334, pp. 66–75, Oct. 2021.
[6] Naito R, Miyauchi K, Daida H, “Racial
Differences in the Cholesterol-Lowering Effect
of Statin,” J. Atheroscler. Thromb., vol. 24, no.
1, p. 19, 2017.
[7] Newman CB, “Statin Safety and Associated
Adverse Events: A Scientific Statement From
the American Heart Association,” Arterioscler.
Thromb. Vasc. Biol., vol. 39, no. 2, pp. E38–E81,
Feb. 2019.
[8] Goldberg KC, “Overcoming inertia: improvement
in achieving target low-density lipoprotein
cholesterol,” Am J Manag Care., vol. 13, no. 9,
p. 540-4, 2007.